Back to top
more

Allergan plc (AGN)

(Delayed Data from NYSE)

$145.81 USD

145.81
1,518,334

+1.56 (1.08%)

Updated May 3, 2019 04:01 PM ET

After-Market: $145.88 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Allergan (AGN) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Allergan (AGN) closed at $166.70 in the latest trading session, marking a +0.15% move from the prior day.

Nilanjan Banerjee headshot

Will Patent Woes Boost Pharma Stock Megamergers Further?

by Nilanjan Banerjee

With key drugs losing exclusivity, key drug makers are poised to face deep trouble since their sales are mostly dependent on a single drug.

Intra-Cellular Therapies' Candidate Fails in Phase III Study

by Zacks Equity Research

Intra-Cellular Therapies' (ITCI) lead candidate fails to meet primary endpoint in one of the phase III studies evaluating it in bipolar depression patients. Shares fall.

AbbVie (ABBV) Shares Down So Far This Year: Here's Why

by Zacks Equity Research

AbbVie's (ABBV) stock suffers a poor run on the bourses due to pipeline setbacks, Humira sales erosion in EU and its proposed offer to buy Allergan.

Editas (EDIT) Focuses on Developing Eye Candidate EDIT-101

by Zacks Equity Research

Editas (EDIT) focuses on the development of its lead candidate, EDIT-101, for treating LCA10, a rare genetic illness that causes blindness. Excessive reliance on partners for revenues remains a woe.

Allergan (AGN) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Allergan (AGN) closed at $169.61, marking a +0.04% move from the previous day.

Can Allergan (AGN) Keep the Earnings Surprise Streak Alive?

by Zacks Equity Research

Allergan (AGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Kinjel Shah headshot

Will the Pharma Space Witness More Mega-Merger Deals in 2H?

by Kinjel Shah

After two mega-mergers, Bristol-Myers/Celgene and AbbVie/Allergan, in first half of 2019, it remains to be seen if more such deals are in store for the second half.

Madhura Bhattacharyya headshot

Email API Platforms Gather Steam: VG, TWLO and AMZN in View

by Madhura Bhattacharyya

Let's take a look at how Vonage (VG), Twilio (TWLO) and Amazon (AMZN) are incorporating email to address the growing needs and preferences of customers in the cloud communications market.

Kinjel Shah headshot

Pharma Stock Roundup: ABBV to Buy AGN, BMY to Sell CELG's Otezla to Close Merger

by Kinjel Shah

AbbVie (ABBV) announces definitive deal to buy Allergan (AGN). Bristol-Myers (BMY) set to sell Celgene's Otezla to complete the impending merger.

Sejuti Banerjea headshot

Is Allergan a Good Deal for AbbVie?

by Sejuti Banerjea

AbbVie is dishing out $63 billion in stock and cash for Allergan, provided it gets regulatory approval.

Sweta Killa headshot

AbbVie to Buy Allergan: Prescribed ETFs

by Sweta Killa

AbbVie has agreed to buy Botox-maker Allergan for $63 billion in a cash-and-stock deal. The news has put the spotlight on a number of healthcare ETFs.

Company News For Jun 26, 2019

by Zacks Equity Research

Companies in the news are: ABBV, AGN, LEN, XNCR, USNA and LION

AbbVie to Acquire Allergan in Nearly $62B Cash & Stock Deal

by Zacks Equity Research

AbbVie (ABBV) offers nearly $63 billion to acquire Botox-maker Allergan to diversify its product portfolio.

The Zacks Analyst Blog Highlights: AbbVie, Allergan, Bristol-Myers and Celgene

by Zacks Equity Research

The Zacks Analyst Blog Highlights: AbbVie, Allergan, Bristol-Myers and Celgene

Axsome Initiates Phase III Study on Depression Candidate

by Zacks Equity Research

Axsome (AXSM) initiates phase III GEMINI study of AXS-05 for the treatment of major depressive disorder.

Daniel Laboe headshot

AbbVie + Allergan: Where Are The Synergies?

by Daniel Laboe

AbbVie (ABBV) is on the hunt for their next big revenue driver as their patent for the world???s top-selling drug, Humira, is nearing its end. AbbVie just made a $63 billion deal to acquire Dublin-based Allergan (AGN) in an attempt to keep their drive alive.

Zachary Stutler headshot

AbbVie (ABBV) Stock Falls After $63 Billion Allergan Acquisition Announcement

by Zachary Stutler

AbbVie announced Tuesday morning its intent to acquire Allergan for $63 billion.

Abbvie Decides to Acquire Allergan

by Zacks Equity Research

Abbvie Decides to Acquire Allergan

Mark Vickery headshot

AbbVie to Buy Botox-Maker Allergan, Look Ahead to G-20

by Mark Vickery

AbbVie (ABBV) has agreed to purchase Botox maker Allergan (AGN) for roughly $63 billion in cash and stock.

Allergan's Botox Wins FDA Nod for Upper Limb Spasticity in Kids

by Zacks Equity Research

Allergan's (AGN) Botox gets FDA approval for the 10th therapeutic indication, upper limb spasticity in pediatric patients, in the age group of 2 to 17 years.

Allergan (AGN) in Focus: Stock Moves 6.2% Higher

by Zacks Equity Research

Allergan (AGN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

The Zacks Analyst Blog Highlights: Amgen, Alexion, Regeneron, Allergan and Savara

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Amgen, Alexion, Regeneron, Allergan and Savara

Company News For Jun 20, 2019

by Zacks Equity Research

Companies In The News Are: VIAB,CBS,ADBE,X,AGN,IRWD

Allergan Up As Analyst Statement Sparks Business Split Rumors

by Zacks Equity Research

Allergan's (AGN) shares up following a conference call with one of the company's executives, which led an analyst to believe that a split of the company's business is in the cards.